Clinical Correlates in Acromegalic Patients with Pituitary Tumors Expressing GSP Oncogenes

Pituitary

Volumn 1, Issue 3-4, 1999, Pages 181-185

  Buchfelder, M ^a,b   Fahlbusch, R ^a   Merz, T ^a   Symowski, H ^a   Adams, E F ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Gs protein; GH; gsp oncogenes, molecular biology; Pituitary adenomas; Somatotrophinomas

Indexed keywords

HORMONE; HUMAN GROWTH HORMONE; OCTREOTIDE; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ACROMEGALY; ADENOMA; BLOOD; CODON; GENE EXPRESSION; GENETICS; GLUCOSE TOLERANCE TEST; HUMAN; HYPOPHYSIS TUMOR; NUCLEOTIDE SEQUENCE; ONCOGENE; POINT MUTATION; REVIEW;

ACROMEGALY; ADENOMA; BASE SEQUENCE; CODON; GENE EXPRESSION; GLUCOSE TOLERANCE TEST; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HORMONES; HUMAN GROWTH HORMONE; HUMANS; OCTREOTIDE; ONCOGENES; PITUITARY NEOPLASMS; POINT MUTATION;

EID: 0033122834     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1009905131334     Document Type: Article

References (17)

1. Fahlbusch R, Honegger J, Buchfelder M. (1992) Surgical management of acromegaly. Endocrinol Metab North America 1992;21:669-692.
2. Adams EF, Brockmeier S, Friedman E, Roth M, Buchfelder M, Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 1993;33:198-203.
3. Hansen LL, Yilmaz M, Overgaard J, Andersen J, Kruse TA. Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. Cancer Res 1998;58: 2166-2169.
4. Klibanski A. Further evidence for a somatic mutation theory in the pathogenesis of human pituitary tumors. J Clin Endocrinol Metab 1990;71:1415A-1415C.
5. s and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692-696.
6. s protein alpha subunit-gsp oncogene is found in human pituitary tumours. Oncogene 1990;5:1059-1061.
7. Adams EF, Lei T, Buchfelder M, Petersen B, Fahlbusch R. Biochemical characteristics of human pituitary somatotrophinomas with and without gsp mutations: In vitro cell culture studies. J Clin Endocrinol Metab 1995;80:2077-2081.
8. Yang IM, Woo JT, Kim SW, Kim YS, Choi YK. Characteristics of acromegalic patients with good response to octreotide, a somatostatin analogue. Clin Endocrinol 1995;42: 295-301.
9. s-alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998;83:1604-1610.
10. s protein. J Clin Endocrinol Metab 1990;71:1416-1420.
11. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G. Clinical, biochemical and morpholgical correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenyl cyclase. J Clin Endocrinol Metab 1990;71:1421-1426.
12. s and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:198-203.
13. Adams EF, Buchfelder M, Lei T, Petersen B, Fahlbusch R. Molecular biology of growth hormone-secreting human pituitary tumours: Biochemical consequences and potential clinical significance. Acta Neurochir (Suppl) 1996;65:7-10.
14. s-alpha mutations. J Clin Endocrinol Metab 1992;75:918-923.
15. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab 1990;71:391-397.
16. Bertherat J, Chanson P, Dewailly D, Dupuy M, Jaquet P, Peillon F, Epelbaum J. Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. J Clin Endocrinol Metab 1993;77:1577-1583.
17. Faglia G. Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinol 1993;129(Suppl 1):1-5.